Imagion Biosystems Limited (ASX: IBX) (Imagion or the Company) is pleased to announce a pro-rata non- renounceable rights issue (Offer) to shareholders, on the basis of 1 new share for every 2 Imagion shares held as at 7.00pm (Melbourne time) Friday 28 September 2018 (Record Date).
View the Pro-Rata Non-Renounceable Rights Issue announcement.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce